Colorectal Cancer Clinical Guidelines
Biomarker-first clinical decision support for colorectal cancer — from Stage II adjuvant decisions and total neoadjuvant therapy in rectal cancer, to RAS/BRAF/dMMR-directed systemic therapy in metastatic disease.
Clinical Guideline Sections
Select a section to access the full treatment algorithm and decision trees.
Early-Stage Colon Cancer
Neoadjuvant indications, adjuvant chemotherapy decisions, Stage II risk stratification, Stage III duration (IDEA, ATOMIC, DYNAMIC-III)
Early-Stage Rectal Cancer
MRI staging, TNT algorithms, organ preservation, Watch & Wait, dMMR/dostarlimab, adjuvant therapy
Metastatic CRC
Biomarker-directed 1L/2L/3L therapy, resectability assessment, conversion strategies, oligometastatic disease
CRC Calculator Hub
Clinical calculators integrated with CRC guidelines — risk stratification, prognosis, geriatric assessment, and supportive care tools.
Clinical reference only. These guidelines are intended to support, not replace, clinical judgment. Treatment decisions should be individualised based on patient-specific factors, local protocols, and multidisciplinary team input. Always apply clinical judgment and consult local institutional guidelines where applicable.